Clinical Trial Update: Expanded Access for Use of bmMSC-Derived Extracellular Vesicles in Patients With COVID-19 Associated ARDS

View source ↗

Summary

Expanded access program for bone marrow mesenchymal stem cell-derived extracellular vesicles in COVID-19-related ARDS is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• bmMSC-Derived Extracellular Vesicles (bone marrow mesenchymal stem cell-derived extracellular vesicles)

Snippet

Sponsor: Direct Biologics, LLC | Conditions: Covid19, ARDS | Status: NO_LONGER_AVAILABLE